# University of Alberta: Phase 2 study closed enrollment, 50 enrolled (Neuroendocrine Tumors)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | University of Alberta |
| Sponsor type | Academic and hospital |
| Study | Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors |
| NCT ID | NCT05255159 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Neuroendocrine Tumors |
| Intervention types | diagnostic test |
| Target enrollment | 50 |
| Site countries | Canada |
| Posted | 2022-02-24 |
| Planned start | 2022-10-15 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-23 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05255159). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.